No results for ‘’
Bliss GVS Pharma Ltd
₹425.30
(7.17%)
Sun, 31 May 2026, 02:20 pm
Health Technology
Pharmaceuticals: Major
24.5KBliss GVS Pharma Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 12.67 | 4.89 | 8.23 | 2.72 | 8.89 | 5.74 | 4.56 | 4.77 | 11.21 | 22.20 | 15.85 | 22.19 | 34.27 | 15 | 10.69 | 15.20 | 53.82 | 10.61 | 15.84 | 14.79 |
| Price to book ratio | 3.37 | 1.37 | 4.58 | 1.05 | 2.78 | 1.40 | 1.14 | 1.07 | 1.60 | 3.95 | 3.17 | 3.74 | 3.76 | 2.87 | 1.41 | 1.26 | 0.97 | 0.84 | 1.22 | 1.18 |
| Price to sales ratio | 2.66 | 0.30 | 2.71 | 0.77 | 2.19 | 1.07 | 0.90 | 0.70 | 1.35 | 3.30 | 2.44 | 4.82 | 5.54 | 2.09 | 1.52 | 1.83 | 1.10 | 1.01 | 1.56 | 1.55 |
| Price to cash flow ratio | 52.24 | 0 | 0 | 6.35 | 66.95 | 10.55 | 6.90 | 0 | 6.47 | 35 | 12.43 | 8.06 | 23.16 | 21.23 | 20.81 | 16.52 | 5.85 | 18.22 | 11.75 | 10.79 |
| Enterprise value | 150.01M | 222.68M | 2.84B | 974.75M | 3.63B | 2.23B | 2.26B | 4B | 5.61B | 14.56B | 14B | 19.61B | 20.56B | 18.65B | 10.77B | 10.38B | 7.69B | 7.79B | 11.14B | 11.63B |
| Enterprise value to EBITDA ratio | 8.27 | 2.37 | 7.41 | 2.49 | 7 | 3.79 | 3.27 | 3.78 | 8.47 | 14.65 | 9.61 | 25.06 | 22.76 | 12.40 | 9.10 | 10.35 | 6.85 | 6.68 | 7.45 | 9.46 |
| Debt to equity ratio | 0.11 | 0.32 | 0.20 | 0.02 | 0.06 | 0.05 | 0.21 | 0.62 | 0.60 | 0.50 | 0.33 | 0.46 | 0.22 | 0.16 | 0.17 | 0.15 | 0.13 | 0.12 | 0.10 | 0.08 |
| Return on equity % | 29.24 | 27.47 | 79 | 46.99 | 36.17 | 27.10 | 27.85 | 24.63 | 15.05 | 19.20 | 22 | 11.31 | 5.84 | 20.93 | 14.08 | 8.87 | 1.85 | 8.32 | 8.15 | 8.36 |
Bliss GVS Pharma Ltd Enterprise Value
The Bliss GVS Pharma Ltd Enterprise Value is a key financial metric used by investors to evaluate Bliss GVS Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Bliss GVS Pharma Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Bliss GVS Pharma Ltd (NSE: BLISSGVS, BSE: 506197) is currently trading at ₹425.30, with a market capitalization of ₹44.94B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Bliss GVS Pharma Ltd Enterprise Value is essential for fundamental analysis.
Bliss GVS Pharma Ltd Enterprise Value Current Value
The current Bliss GVS Pharma Ltd Enterprise Value stands at 11.63B.
The latest Bliss GVS Pharma Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Bliss GVS Pharma Ltd Enterprise Value Historical Trend
The Bliss GVS Pharma Ltd Enterprise Value has shown the following historical trend:
- 2024: 11.63B
- 2023: 11.14B
- 2022: 7.79B
- 2021: 7.69B
- 2020: 10.38B
The recent rise in Bliss GVS Pharma Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Bliss GVS Pharma Ltd Enterprise Value Indicates for Investors
The Bliss GVS Pharma Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Bliss GVS Pharma Ltd.
Bliss GVS Pharma Ltd Enterprise Value Analysis Summary
The Bliss GVS Pharma Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Bliss GVS Pharma Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Bliss GVS Pharma Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.